PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

NEW YORK, May 14, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
http://www.reportlinker.com/p01171136/PharmaSphere-Early-Stage-Technology-Transfer-Collaborations---Enabling-Platform-Technologies--Deal-Synergies-between-Academia-and-the-Pharmaceutical-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

Summary

"PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry" report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData's Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry's attempts at moving toward an open R&D ecosystem.

Highlights

Key Questions Answered

- What are the reasons for increased activity in strategic deals with academia by leading pharmaceutical companies and promising biotechs?
- What are the deal terms of these collaboration agreements?
- What therapeutic areas and geographic markets are pharmaceutical companies targeting to partner with academic research institutions?
- What proprietary platforms and enabling technologies are these pharmaceutical companies trying to access?

Key Findings

- With the patent cliff and high R&D costs eroding corporate profitability, pharmaceutical companies will look for ways to replenish their pipelines by reaching out to academia in search of novel drug platforms
- Despite the FDA approving 39 new drugs in 2012, the innovation gap continues, as many of these medicines are 'me-too' drugs, or orphan drugs indicated to treat small segments of the population suffering from rare diseases
- Difficulty accessing capital and the continued economic recession have led to a deal adverse environment resulting in deals to decline on a global basis
- Oncology, CNS, immunology and infectious diseases still remain hot therapeutic areas to strike licensing deals with academia

Scope

- Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms
- Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas
- Discussion of the unsustainability of the current drug research model and how Big Pharma's embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery
- Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer
- Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies
- Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, 'Big Data' and drug recycling/repurposing approaches

Key Benefits

- Analyze and track the strategies that these pharmaceutical companies are using to gain share in an increasingly competitive marketplace
- Target academic institutions with novel and proprietary technologies to maximize opportunities for strategic investment or partnerships
- Formulate effective licensing strategies by understanding the various factors and deal terms considered when structuring tech-transfer partnerships
- Use information as an independent source for your due diligence and transaction strategies

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 About PharmaSphere Report Series 13
3 A Changing and Challenging Deal Making Landscape 14
3.1 Overview 14
3.2 Deal Drivers 15
3.2.1 The Patent Cliff 15
3.2.2 Deal-Adverse Environment 18
3.2.3 Spike in Regulatory Approvals but Innovation Gap Continues 22
3.2.4 FDA's Proposal to Lower Regulatory Standards in Early-Stage Alzheimer's Research 23
3.2.5 More Stringent Regulatory Regime in a Post-Vioxx and Avandia World 24
3.2.6 Viewpoint: Vioxx and Avandia Cases 25
4 An Unsustainable R&D Paradigm 27
4.1 Big Pharma's Embrace of Disruptive Innovation May Fix Broken R&D Model 28
4.1.1 Pre-Competitive Information Sharing 28
4.1.2 Open-Source Patient Data 29
4.1.3 'Big Data' and Drug Discovery 30
4.1.4 Tech Transfer in Action: Astellas Pharma Taps IT for Drug Discovery 31
4.1.5 Drug Recycling 31
4.1.6 Viewpoint: Drug Repurposing at NCATS 32
4.1.7 Tech Transfer in Action: Roche & Broad Join to Bring Failed Drugs Back from the Dead 33
5 Major Global Technology Transfer Alliances 34
5.1 The Bayh-Dole Act of 1980 34
5.2 Deals Overview 36
5.3 Biscayne Pharma Enters into Licensing Agreement with University of Miami for Growth Hormone-Releasing Technology 40
5.3.1 Deal Summary 40
5.3.2 Deal Analysis 40
5.4 Genoa Pharma Enters into Research Agreement with McMaster University for IPF 42
5.4.1 Deal Summary 42
5.4.2 Deal Analysis 42
5.5 AstraZeneca Partners with Vanderbilt University for Neuroscience Drug Discovery 44
5.5.1 Deal Summary 44
5.5.2 Deal Analysis 44
5.6 Trovagene Grants License for NPM1 Marker for AML to Duke University 45
5.6.1 Deal Summary 45
5.6.2 Deal Analysis 45
5.7 Synthetic Biologics and University of Texas Ink Research Deal to Fight Pertussis 47
5.7.1 Deal Summary 47
5.7.2 Deal Analysis 47
5.8 BMS and Vanderbilt University Sign Deal to Develop Drugs for Parkinson's 49
5.8.1 Deal Summary 49
5.8.2 Deal Analysis 49
5.9 AstraZeneca and Broad Institute Partner to Advance Discovery of Antibacterial and Antiviral Agents 50
5.9.1 Deal Summary 50
5.9.2 Deal Analysis 50
5.10 Bayer HealthCare Opens New Lab Space – The CoLaborator – for Biotech Startups 51
5.10.1 Deal Summary 51
5.10.2 Deal Analysis 51
5.11 Novartis Enters into Licensing Agreement with Penn for CART-19 53
5.11.1 Deal Summary 53
5.11.2 Deal Analysis 53
5.12 Sanofi and BWH Agree to Develop Antibodies for Type 1 Diabetes 55
5.12.1 Deal Summary 55
5.12.2 Deal Analysis 55
5.13 AstraZeneca and Leading Academic Organizations Collaborate on Alzheimer's Research 56
5.13.1 Deal Summary 56
5.13.2 Deal Analysis 56
5.14 Novo Nordisk Enters into R&D Agreement with JDRF for Type 1 Diabetes 57
5.14.1 Deal Summary 57
5.14.2 Deal Analysis 57
5.15 Large Pharmas Unite with the Genome Institute of Singapore to Combat Cancer in Asian Populations 58
5.15.1 Deal Summary 58
5.15.2 Deal Analysis 58
5.15.3 Tech Transfer in Action: National University Singapore Startup AyoxxA Biosystems 59
5.16 University of Washington and 'Big Pharma' Join Forces to Research Drug Transporters 60
5.16.1 Deal Summary 60
5.16.2 Deal Analysis 60
5.17 Pharma and the University of Dundee Create Consortium on Cell Signaling Research 61
5.17.1 Deal Summary 61
5.17.2 Deal Analysis 61
5.18 Novo Nordisk and Oxford Join to Identify Novel Biomarkers for Rheumatoid Arthritis 62
5.18.1 Deal Summary 62
5.18.2 Deal Analysis 62
5.19 Elan Corporation and University of Cambridge Enter into Joint Venture to Discover New Therapies Targeting Neurodegenerative Disorders 63
5.19.1 Deal Summary 63
5.19.2 Deal Analysis 63
5.20 GSK and Yale Partner to Develop New Drugs Targeting Disease-Causing Proteins 64
5.20.1 Deal Summary 64
5.20.2 Deal Analysis 64
5.21 Big Pharma Companies and Research Institutions Tackle Early-Stage Research TB 65
5.21.1 Deal Summary 65
5.21.2 Deal Analysis 65
5.22 Accuray Signs Collaboration Agreement with University of Heidelberg to Provide Cutting-edge Research in Radiation Oncology 66
5.22.1 Deal Summary 66
5.22.2 Deal Analysis 66
5.23 UCB and Oxford University Join to Focus on Developing Innovative Medicines for Immunological and Neurological Disorders 67
5.23.1 Deal Summary 67
5.23.2 Deal Analysis 67
5.24 Large Pharma and King's College London Establish a Center to Tackle Autism 69
5.24.1 Deal Summary 69
5.24.2 Deal Analysis 69
5.25 Merck Establishes an Independent Non-profit Drug Research Institute – the California Institute for Biomedical Research 70
5.25.1 Deal Summary 70
5.25.2 Deal Analysis 70
5.26 J&J and University of Queensland Develop Drugs Using Spider Venom for Treating Pain 71
5.26.1 Deal Summary 71
5.26.2 Deal Analysis 71
5.27 Sanofi and UCSF Form a Pact to Work on New Treatments for Diabetes 73
5.27.1 Deal Summary 73
5.27.2 Deal Analysis 73
5.27.3 Tech Transfer in Action: Tufts University Spin-off Anchor Therapeutics 74
6 Future Outlook 76
7 Appendix 77
7.1 Research Methodology 77
7.1.1 Coverage 77
7.1.2 Secondary Research 77
7.1.3 Expert Panel Validation 78
7.2 About the Author 78
7.2.1 Analyst 78
7.3 Director, Healthcare Industry Dynamics 79
7.4 Global Head of Healthcare 79
7.5 About the Industry Dynamics Team 79
7.6 GlobalData 80
7.7 Contact Us 80
7.8 Disclosure Information 80
7.9 Disclaimer 80

List of Tables

Table 1: Recent and Upcoming US Patent Expirations with FY2011 and FY2012 Sales Data 16
Table 2: Deals Summary of Major Technology Transfer Alliances, January 2012–January 2013 38
Table 3: Biscayne Pharma & University of Miami, Deal Summary, 2013 40
Table 4: Genoa Pharma & McMaster University, Deal Summary, 2013 42
Table 5: AstraZeneca & Vanderbilt University, Deal Summary, 2013 44
Table 6: Trovagene & Duke University, Deal Summary, 2012 45
Table 7: Synthetic Biologics & University of Texas, Deal Summary, 2012 47
Table 8: BMS & Vanderbilt University, Deal Summary, 2012 49
Table 9: AstraZeneca & Broad Institute, Deal Summary, 2012 50
Table 10: Bayer HealthCare & Aronora, ProLynx, Deals Summary 2012 51
Table 11: Novartis & University of Pennsylvania, Deal Summary 2012 53
Table 12: Sanofi & Brigham and Women's Hospital, Deal Summary 2012 55
Table 13: AstraZeneca & Leading Academic Organizations, Deal Summary 2012 56
Table 14: Novo Nordisk & JDRF, Deal Summary 2012 57
Table 15: Eli Lilly, Merck, Pfizer & Genome Institute of Singapore, Deal Summary 2012 58
Table 16: AZ, Genentech, Merck & University of Washington in St. Louis, Deal Summary 2012 60
Table 17: Pharma & University of Dundee, Deal Summary 2012 61
Table 18: Novo Nordisk & University of Oxford, Deal Summary 2012 62
Table 19: Elan Corporation & University of Cambridge, Deal Summary 2012 63
Table 20: GSK & Yale University, Deal Summary 2012 64
Table 21: Pharma & Texas A&M University and Cornell Medical College, Deal Summary 2012 65
Table 22: Accuray & University of Heidelberg, Deal Summary 2012 66
Table 23: UCB & Oxford University, Deal Summary 2012 67
Table 24: Eli Lilly, Janssen, Pfizer, Roche & Kings College London, Deal Summary 2012 69
Table 25: Merck, Pharma & Biotech Start-ups, Deal Summary 2012 70
Table 26: Johnson & Johnson & University of Queensland, Deal Summary 2012 71
Table 27: Sanofi & University of California at San Francisco, Deal Summary 2012 73

List of Figures

Figure 1: Lipitor Sales WW vs. US, 4Q11–4Q12 15
Figure 2: Pharmaceuticals and Healthcare, Number of Deals and Deal Values (US $m), Globally from September 2012 – February 2013 18
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, February 2013 19
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, February 2013 20
Figure 5: FDA Drug Approvals, 1995–2012 22
Figure 6: Academic Technology Transfer Deals and Deal Values (US $m), from 2007–2012 36

To order this report:
Drug_and_Medication Industry: PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker